Status:
COMPLETED
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
Lead Sponsor:
Mayo Clinic
Conditions:
Healthy
Clostridium Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons wit...
Eligibility Criteria
Inclusion
- Table 1. Inclusion Criteria for Healthy Volunteers:
- 1\. Healthy individuals without chronic gastrointestinal problems or using antisecretory medications.
- Table 2. Inclusion Criteria for Clostridium difficile infection subjects:
- 1\. Newly diagnosed first episode of CDI prior to being treated.
- Table 3. Exclusion Criteria for Healthy Subjects:
- Prior gastrointestinal surgery that has altered the anatomy of the esophagus, stomach, or small/large intestine including appendectomy and cholecystectomy.
- Chronic daily use of any medications that could alter gastrointestinal secretory or motor function (see Table 2).
- Gastrointestinal, cardiovascular, endocrine, renal, or other chronic disease likely to affect gastrointestinal motility (e.g., uncontrolled diabetes mellitus).
- Females of childbearing age who are not practicing at least one form of birth control at least one month prior to starting the PPI or are pregnant or lactating (a pregnancy test will be performed on female subjects prior to PPI use).
- Significant untreated psychiatric disease.
- Table 4. Prohibited Medications:
- Antibiotics within 2 months of the stool sample collection.
- Probiotics (e.g., Florastor, Align, Flora-Q, VSL#3, lactobacillus, bifidobacterium) within 2 weeks of the stool sample collection.
- Fiber supplements (e.g., Metamucil, Citrucel, Benefiber), unless maintained on a stable dose for the last 3 months.
- Chronic use of medications that alter gastric pH: proton pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole) and histamine2 receptor antagonists (e.g., cimetidine, famotidine, ranitidine).
- Chronic use of medications that affect gastrointestinal motility and/or transit including prokinetic agents (e.g., metoclopramide (Reglan), tegaserod (Zelnorm), domperidone (Motilium), erythromycin), narcotic analgesic agents (e.g., methadone, fentanyl, oxycodone, codeine, morphine, hydromorphone), laxatives including mineral oil, anticholinergic agents (e.g., Bentyl, Levsin), and antidiarrheal agents (e.g., Kaopectate (donnagel), Pepto-Bismol (bismuth subsalicylate), Imodium (loperamide), Lomotil (atropine with diphenoxylate), codeine, tincture of opium).
Exclusion
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01822977
Start Date
March 1 2013
End Date
December 1 2013
Last Update
August 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259